Dyadic International, Inc. (Dyadic Applied BioSolutions)

Dyadic International, Inc., operating as Dyadic Applied BioSolutions, is a global biotechnology platform company headquartered in Jupiter, Florida, USA. The company's mission is to expand access to essential proteins by making biomanufacturing faster, more affordable, and more scalable, partnering across various industries to unlock new possibilities in life science, food and nutrition, and industrial biotechnology applications.

Dyadic leverages its proprietary microbial expression systems, primarily the C1 and Dapibus™ platforms, to produce high-value, precision-engineered recombinant proteins. These platforms are designed for efficient, large-scale manufacturing of proteins for non-therapeutic applications, thereby avoiding the regulatory complexities and high costs associated with therapeutic biologics. Key market segments include life sciences, food and nutrition, and bio-industrial applications, with specific products such as recombinant human albumin (AlbuFree™ DX), animal-free recombinant DNase I, human alpha-lactalbumin, human lactoferrin, non-animal dairy enzymes, and bovine FGF.

In 2025, Dyadic International, Inc. strategically rebranded to Dyadic Applied BioSolutions, reflecting a shift towards commercializing high-value, non-therapeutic proteins. The company is transitioning from an R&D-driven model to a commercially focused provider of ancillary recombinant protein products, actively launching new products and establishing distribution partnerships. Mark Emalfarb serves as the Founder and Chief Executive Officer, while Joe Hazelton was appointed President and Chief Operating Officer in 2025.